docetaxel, cisplatin and 5-fluorouracil

DRUG2 trials

Sponsors

Centre Hospitalier Universitaire de Besancon, Shanghai Jiao Tong University School of Medicine

Conditions

Anal Canal CarcinomaNeoplasm Neck

Phase 2

Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal Carcinoma

CompletedNCT02402842

Centre Hospitalier Universitaire de BesanconAnal Canal Carcinoma

Start: 2014-09-30End: 2020-06-30Updated: 2022-05-16

Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC

RecruitingNCT03326947

Shanghai Jiao Tong University School of MedicineNeoplasm Neck

Start: 2018-01-01End: 2027-01-01Target: 60Updated: 2024-02-20

Related Papers

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

Frontiers in Oncology2022-08-248 citations

Kim S, François E, André T, et al. (2018) Lancet Oncol 19:1094–106 Schéma de chimiothérapie associant docétaxel, cisplatine et fluoro-uracile pour le traitement d’un carcinome épidermoïde anal localement récurrent métastatique ou non résécable (Épitopes HPV02) : une étude multicentrique de phase 2 à bras unique

Côlon & Rectum2019-05-01

HPV circulating tumor DNA as predictive biomarker of sustained response to chemotherapy in advanced anal carcinoma

Annals of Oncology2018-10-012 citations

Docetaxel, cisplatin, and fluorouracil chemotherapy for metastatic or unresectable locally recurrent anal squamous cell carcinoma (Epitopes-HPV02): a multicentre, single-arm, phase 2 study.

2018-07-0287 citations

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study).

2017-08-2516 citations